The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ:SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback